Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 21, 2026 16:05 ET | Source: Immuneering Corporation

Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has...
July 17, 2026 16:05 ET | Source: Immuneering Corporation

Immuneering Corporation Announces Grants of Inducement Awards

Immuneering Corporation Announces Grants of Inducement Awards
June 15, 2026 07:30 ET | Source: Immuneering Corporation

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Immuneering Appoints Andrew Gengos as Chief Financial Officer
June 11, 2026 07:30 ET | Source: Immuneering Corporation

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 04, 2026 12:07 ET | Source: Allsup

Allsup Highlights Pancreatic Cancer Research And Importance Of Timely SSDI Applications

Belleville, Illinois, June 04, 2026 (GLOBE NEWSWIRE) -- Allsup, a leading provider of Social Security Disability Insurance (SSDI) representation, return to work and veterans disability appeals...
June 01, 2026 07:30 ET | Source: Immuneering Corporation

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Can
May 21, 2026 17:00 ET | Source: Immuneering Corporation

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
May 15, 2026 07:35 ET | Source: Immuneering Corporation

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
April 22, 2026 11:00 ET | Source: NETRIS Pharma

NETRIS Pharma: Nature publishes positive pancreatic cancer Phase 1b data for NP137 anti-netrin-1 monoclonal antibody

Positive results from “LAPNET-01,” phase 1b trial of NP137 in patients with pancreatic ductal adenocarcinoma, published in Nature.
April 21, 2026 16:05 ET | Source: Immuneering Corporation

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO...